In a significant move that is set to reshape the biopharmaceutical landscape, Tanvex BioPharma is acquiring Bora Biologics, a subsidiary of Bora Pharmaceuticals. This strategic merger aims to amalgamate the strengths of two industry leaders, creating a formidable force in the global Contract
Enhancing Manufacturing Capabilities Novartis is making significant strides in its efforts to expand manufacturing capabilities to meet the growing demand for radiopharmaceutical therapies aimed at treating cancer. To achieve this, the company is not only expanding an existing facility in
In a strategic move to enhance its offerings in the biopharmaceutical sector, BioPhorum has announced the acquisition of Brookwood Global, a renowned UK-based training and educational content provider specializing in clinical research and drug safety. For over 15 years, BioPhorum has been a key
AstraZeneca has set the wheels in motion to significantly expand its biomanufacturing capacities with a $135 million investment in the Sweden Biomanufacturing Center in Södertälje. This venture marks the company's largest single investment in the facility since its inception in 2021, i
Bora Pharmaceuticals' recent strategic maneuvers have significantly bolstered its presence in the Contract Development and Manufacturing Organization (CDMO) sector, showcasing its intent to become a top contender in the biomanufacturing industry. In a notable move, Bora has acquired a 30.5%
Bora Pharmaceuticals continues its robust expansion by acquiring a significant operational stake in Tanvex BioPharma, a deal set to close in early 2025. This strategic acquisition positions Bora as the largest shareholder in Tanvex, granting the company access to a commercial-scale production
